Cyclical regulation of the insulin-like growth factor binding protein 3 gene in response to 1α,25-dihydroxyvitamin D3
暂无分享,去创建一个
Jussi Ryynänen | Merja Heinäniemi | Marjo Malinen | Sami Väisänen | Carsten Carlberg | C. Carlberg | M. Heinäniemi | S. Väisänen | Marjo Malinen | Jussi Ryynänen | M. Malinen
[1] D. S. Broomhead,et al. Pulsatile Stimulation Determines Timing and Specificity of NF-κB-Dependent Transcription , 2009, Science.
[2] M. Haussler,et al. The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] Z. Gucev,et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. , 1996, The international journal of biochemistry & cell biology.
[4] N. Pejnović,et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. , 1999, Clinical and experimental rheumatology.
[5] J. Chen,et al. The SRC family of nuclear receptor coactivators. , 2000, Gene.
[6] P. Cohen,et al. Rapid Apoptosis Induction by IGFBP-3 Involves an Insulin-like Growth Factor-independent Nucleomitochondrial Translocation of RXRα/Nur77* , 2005, Journal of Biological Chemistry.
[7] M. Groudine,et al. Controlling the double helix , 2003, Nature.
[8] C. Carlberg,et al. Regulation of multiple insulin-like growth factor binding protein genes by 1α,25-dihydroxyvitamin D3 , 2005, Nucleic acids research.
[9] G. Pirianov,et al. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. , 1999, European journal of cancer.
[10] P. Lips. Vitamin D physiology. , 2006, Progress in biophysics and molecular biology.
[11] F. Dequiedt,et al. Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.
[12] C. Fullmer,et al. Vitamin D and intestinal calcium transport: facts, speculations and hypotheses. , 1995, The Journal of nutrition.
[13] P. Becker,et al. Energy‐dependent chromatin accessibility and nucleosome mobility in a cell‐free system. , 1995, The EMBO journal.
[14] Sungtae Kim,et al. 1,25‐Dihydroxyvitamin D3 Stimulates Cyclic Vitamin D Receptor/Retinoid X Receptor DNA‐Binding, Co‐activator Recruitment, and Histone Acetylation in Intact Osteoblasts , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] B. Turner,et al. An increasingly complex code. , 2002, The Journal of clinical investigation.
[16] C. Carlberg. The impact of transcriptional cycling on gene regulation , 2010, Transcription.
[17] M. Uskoković,et al. A 1α,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice , 2002 .
[18] F. Dequiedt,et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.
[19] R. Simpson,et al. c-myc Intron Element-binding Proteins Are Required for 1,25-Dihydroxyvitamin D3 Regulation of c-myc during HL-60 Cell Differentiation and the Involvement of HOXB4* , 1999, The Journal of Biological Chemistry.
[20] R. Baxter. Insulin-like growth factor binding proteins in the human circulation: a review. , 1994, Hormone research.
[21] R. Bouillon,et al. Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.
[22] A. Nohe,et al. Molecular basis of the potential of vitamin D to prevent cancer , 2008, Current medical research and opinion.
[23] J. Welsh,et al. Vitamin D(3) receptor ablation alters mammary gland morphogenesis. , 2002, Development.
[24] S. Nagpal,et al. Noncalcemic actions of vitamin D receptor ligands. , 2005, Endocrine reviews.
[25] Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. , 1999, Endocrinology.
[26] Xiao-Fan Wang,et al. HDAC6 is a microtubule-associated deacetylase , 2002, Nature.
[27] K. Umesono,et al. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.
[28] C. Mathieu,et al. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3 , 1994, Diabetologia.
[29] C. Carlberg,et al. Corepressor excess shifts the two-side chain vitamin D analog Gemini from an agonist to an inverse agonist of the vitamin D receptor. , 2003, Molecular endocrinology.
[30] D. Steinhilber,et al. Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. , 2007, Biochimica et biophysica acta.
[31] J. Auwerx,et al. Sirtuin functions in health and disease. , 2007, Molecular endocrinology.
[32] J. Welsh. Targets of Vitamin D Receptor Signaling in the Mammary Gland , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] R. Bouillon,et al. Nonhypercalcemic vitamin D analogs: interactions with the vitamin D-binding protein. , 1996, Hormone research.
[34] F. Dequiedt,et al. Human HDAC7 Histone Deacetylase Activity Is Associated with HDAC3in Vivo * , 2001, The Journal of Biological Chemistry.
[35] P. Yamada,et al. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. , 2009, American journal of physiology. Cell physiology.
[36] E. Giovannucci,et al. Vitamin D and prevention of breast cancer: Pooled analysis , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[37] B. Turner,et al. Cellular Memory and the Histone Code , 2002, Cell.
[38] Craig L. Peterson,et al. Chromatin Higher Order Folding--Wrapping up Transcription , 2002, Science.
[39] J. Welsh. Vitamin D and prevention of breast cancer , 2007, Acta Pharmacologica Sinica.
[40] P. Yin,et al. Paradoxical Actions of Endogenous and Exogenous Insulin-like Growth Factor-binding Protein-5 Revealed by RNA Interference Analysis* , 2004, Journal of Biological Chemistry.
[41] R. Evans,et al. Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.
[42] M. Lambert,et al. Activation of nuclear receptors: a perspective from structural genomics. , 2003, Structure.
[43] Elina Hyppönen,et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study , 2001, The Lancet.
[44] T. Cotter,et al. Histone deacetylase activity in conjunction with E2F‐1 and p53 regulates Apaf‐1 expression in 661W cells and the retina , 2009, Journal of neuroscience research.
[45] C. Carlberg,et al. Gene regulation by vitamin D3. , 1998, Critical reviews in eukaryotic gene expression.
[46] R. Baxter,et al. IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. , 2002, Endocrinology.
[47] T. Kouzarides,et al. Regulation of E2F1 activity by acetylation , 2000, The EMBO journal.
[48] R. Radulescu,et al. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. , 1997, Endocrinology.
[49] Jose Russo,et al. Human Breast Epithelial Cell Line, MCF-10 Isolation and Characterization of a Spontaneously Immortalized , 2006 .
[50] A. Aranda,et al. Synergistic activation of the prolactin promoter by vitamin D receptor and GHF-1: role of the coactivators, CREB-binding protein and steroid hormone receptor coactivator-1 (SRC-1). , 1999, Molecular endocrinology.
[51] B. Hollis. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.
[52] C. Carlberg,et al. Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. , 2006, Current topics in medicinal chemistry.
[53] L. Freedman,et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.
[54] D. Trump,et al. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.
[55] C. Carlberg,et al. Ligand-triggered stabilization of vitamin D receptor/retinoid X receptor heterodimer conformations on DR4-type response elements. , 2000, Journal of molecular biology.
[56] C. Carlberg,et al. Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter , 2005, Nucleic acids research.
[57] C. Carlberg,et al. VDR‐Alien: a novel, DNA‐selective vitamin D3 receptor‐corepressor partnership , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] V. Hwa,et al. The Insulin-like Growth Factor-binding Protein (igfbp) Superfamily* , 2022 .
[59] Neil J. McKenna,et al. Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.
[60] A. Ascherio,et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.
[61] C. Monneret,et al. Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.
[62] C. Carlberg,et al. New vitamin D receptor ligands , 2003 .
[63] H. Huynh,et al. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. , 1999, The Journal of endocrinology.
[64] H. DeLuca. Overview of general physiologic features and functions of vitamin D. , 2004, The American journal of clinical nutrition.
[65] C. Tepper,et al. 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. , 1993, Experimental cell research.
[66] C. Carlberg,et al. Vitamin D Receptor Agonists Specifically Modulate the Volume of the Ligand-binding Pocket* , 2006, Journal of Biological Chemistry.
[67] C. Carlberg. Ligand-mediated conformational changes of the VDR are required for gene transactivation , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[68] G. Martino,et al. Inhibition of Th1 development and treatment of chronic‐relapsing experimental allergic encephalomyelitis by a non‐hypercalcemic analogue of 1,25‐dihydroxyvitamin D3 , 2000, European journal of immunology.
[69] Heike Brand,et al. Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter , 2003, Cell.
[70] C. Perks,et al. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. , 1998, Journal of molecular endocrinology.
[71] R. Bouillon,et al. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells , 1998, Molecular and Cellular Endocrinology.
[72] M. Grunstein. Histone acetylation in chromatin structure and transcription , 1997, Nature.
[73] C. Carlberg,et al. Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. , 2001, The Journal of investigative dermatology.
[74] J. Clifford,et al. Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-α Regulate Transcriptional Signaling and Apoptosis* , 2000, The Journal of Biological Chemistry.
[75] T. Shinki,et al. Vitamin D and bone , 2003, Journal of cellular biochemistry.
[76] P. Becker. Nucleosome sliding: facts and fiction , 2002, The EMBO journal.
[77] H. Pols,et al. Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[78] J. Welsh,et al. Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. , 2004, Molecular endocrinology.
[79] A. V. van Kuilenburg,et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.
[80] Anna Saramäki,et al. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to trichostatin A and 1α,25-dihydroxyvitamin D3 , 2007, Nucleic acids research.
[81] R. Baxter,et al. Insulin-like Growth Factor-binding Protein (IGFBP)-3 and IGFBP-5 Share a Common Nuclear Transport Pathway in T47D Human Breast Carcinoma Cells* , 1998, The Journal of Biological Chemistry.
[82] Vincent Laudet,et al. International Union of Pharmacology. LXVI. Orphan Nuclear Receptors , 2006, Pharmacological Reviews.
[83] D. Leroith,et al. Membrane-associated Insulin-like Growth Factor-binding Protein-3 Inhibits Insulin-like Growth Factor-I-induced Insulin-like Growth Factor-I Receptor Signaling in Ishikawa Endometrial Cancer Cells* , 1997, The Journal of Biological Chemistry.
[84] C. Carlberg,et al. Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists. , 2000, Molecular pharmacology.
[85] Yong Ming Li,et al. Regulation of Myeloid Growth and Differentiation by the Insulin-Like Growth Factor I Receptor1. , 1997, Endocrinology.
[86] C. Allis,et al. Translating the Histone Code , 2001, Science.
[87] A. Howell,et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. , 2006, Endocrine-related cancer.
[88] S. Grewal,et al. Heterochromatin: silence is golden , 2003, Current Biology.
[89] C. Mathieu,et al. Non-hypercalcemic pharmacological aspects of vitamin D analogs. , 1995, Biochemical pharmacology.
[90] C. Carlberg,et al. Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor. , 2003, Molecular pharmacology.
[91] Anna Saramäki,et al. Controlling the chromatin organization of vitamin D target genes by multiple vitamin D receptor binding sites , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[92] C. Mathieu,et al. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. , 1995, Endocrinology.
[93] M. Pollak,et al. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. , 1999, International journal of oncology.
[94] S. Leal,et al. The Type V Transforming Growth Factor β Receptor Is the Putative Insulin-like Growth Factor-binding Protein 3 Receptor* , 1997, The Journal of Biological Chemistry.
[95] Nick Gilbert,et al. Chromatin Architecture of the Human Genome Gene-Rich Domains Are Enriched in Open Chromatin Fibers , 2004, Cell.
[96] C. Carlberg,et al. Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene. , 2009, Journal of molecular biology.
[97] M. Webber,et al. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. , 1997, Carcinogenesis.
[98] Anna Saramäki,et al. Cyclical Chromatin Looping and Transcription Factor Association on the Regulatory Regions of the p21 (CDKN1A) Gene in Response to 1α,25-Dihydroxyvitamin D3*S⃞ , 2009, Journal of Biological Chemistry.
[99] D. Feldman,et al. The role of vitamin D in prostate cancer , 2001, Steroids.
[100] H. DeLuca,et al. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. , 2000, Archives of biochemistry and biophysics.
[101] Paul Tempst,et al. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.
[102] Ivan V. Gregoretti,et al. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.
[103] P. Malloy,et al. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. , 2004, Molecular endocrinology.
[104] C. Allis,et al. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. , 1996, Current opinion in genetics & development.
[105] C. Carlberg,et al. Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. , 2005, Journal of molecular biology.
[106] N. Pejnović,et al. Disease modifying and immunomodulatory effects of high dose 1 ( OH ) D 3 in rheumatoid arthritis patients , 2006 .
[107] M. Jäättelä,et al. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. , 1999, Cancer research.
[108] H. Erdjument-Bromage,et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. , 1998, Genes & development.
[109] C. Carlberg,et al. All natural DR3-type vitamin D response elements show a similar functionality in vitro. , 2000, The Biochemical journal.
[110] P. Cohen,et al. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. , 2001, The Journal of urology.
[111] J. Hansen,et al. Conformational dynamics of the chromatin fiber in solution: determinants, mechanisms, and functions. , 2002, Annual review of biophysics and biomolecular structure.
[112] Matthias Egger,et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.
[113] G. Gill,et al. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? , 2004, Genes & development.
[114] E. Zimmermann,et al. Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[115] C. Carlberg,et al. Natural vitamin D3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation , 1995, Molecular and cellular biology.
[116] E. Froesch,et al. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. , 1989, Acta endocrinologica.
[117] Martin Lipkin,et al. The role of vitamin D in cancer prevention. , 2006, American journal of public health.
[118] P. Shaw,et al. Gene activation and deactivation related changes in the three-dimensional structure of chromatin , 2005, Chromosoma.
[119] C. Carlberg,et al. Gene regulatory potential of 1α,25‐dihydroxyvitamin D3 analogues with two side chains , 2001, Journal of cellular biochemistry. Supplement.
[120] H. Koeffler,et al. Characterization of a novel analogue of 1alpha,25(OH)(2)-vitamin D(3) with two side chains: interaction with its nuclear receptor and cellular actions. , 2000, Journal of medicinal chemistry.
[121] S. Velasco-Miguel,et al. Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.
[122] A. Howie,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Extrarenal Expression of 25-Hydroxyvitamin , 2022 .